Skip to content

Key resources

  • Bibliography
    Bibliography
  • Health promotion
    Health promotion
  • Health practice
    Health practice
  • Yarning places
    Yarning places
  • Programs
    Programs
  • Organisations
    Organisations
  • Conferences
    Conferences
  • Courses
    Courses
  • Funding
    Funding
  • Jobs
    Jobs
Australian Indigenous HealthBulletin
 
  • Home
    • » Key resources and services
      • » Programs and projects
        • » Using pneumococcal conjugate vaccines, Synflorix and Prevenar 13 in sequence or alone, in high risk Indigenous infants for maximum protection from ear infections

Using pneumococcal conjugate vaccines, Synflorix and Prevenar 13 in sequence or alone, in high risk Indigenous infants for maximum protection from ear infections

 

Overview

This randomised control trial aims to determine whether early commencement of a sequential schedule of two pneumococcal conjugate vaccines, Pneumococcal Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV or Synflorix) and 13-valent pneumococcal conjugate vaccine (PCV13 or Prevenar13), given in sequence at one, two, four (PHiD-CV), and 6 months (PCV13), gives greater protection against otitis media compared to either PCV13-alone or PHiD-CV-alone at two, four, and six months.

The project is funded by the National Health and Medical Research Council (NHMRC) and began in August 2011, expecting to be completed in 2014.

Contacts

Child Health Division
Menzies School of Health Research
PO Box 41096
Casurina NT 0811
Ph: (08) 8922 8196
Fax: (08) 8927 5187
Email: earinfonet@menzies.edu.au

Links

 
Last updated: 4 June 2014
 
Return to top